Clinical trials · Tennessee
Down Syndrome clinical trials in Tennessee
We’re tracking 93 recruiting down syndrome studies with a site in Tennessee — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Tennessee
- NCT07216443RecruitingPhase 2
Study of orca-t for leukemia or MDS with reduced intensity chemo
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
Nashville, TennesseeAges 18 years+ - NCT07189936RecruitingPhase 2
Testing 2-HOBA for Immune Issues in Long COVID with POTS
This trial tests if a medication called 2-HOBA can help with ongoing immune system issues in people with Long COVID who also have POTS. It aims to reduce fatigue and other symptoms by calming overactive immune responses.
Nashville, TennesseeAges 18 years+ - NCT07135167RecruitingPhase 3
Epi-ON corneal crosslinking study for people with Down syndrome
This study tests a special light treatment for cornea problems in people with Down syndrome. It aims to strengthen the front of the eye and may help prevent vision loss.
Chattanooga, TennesseeAges 8 years+ - NCT06907849Enrolling by invitationPhase 2
Imaging amyloid in spinal stenosis and carpal tunnel
This trial tests a special scan that uses a radioactive tracer to look for amyloid protein deposits in people who have had surgery for lumbar spinal stenosis (narrowing of the spine in the lower back) or carpal tunnel syndrome. The goal is to see if the scan can detect these deposits, which may be linked to ongoing orthopedic issues.
Knoxville, TennesseeAges 60 years+ - NCT06899178RecruitingPhase 2
Atomoxetine for genetic obesity due to MC4R changes
This trial tests a medicine called atomoxetine (Strattera) to help people with a specific genetic form of obesity lose weight. It may be an option if you have a change in the MC4R gene and have not used certain other medications recently.
Nashville, TennesseeAges 6 years+ - NCT06872125RecruitingPhase 3
Testing zorevunersen for Dravet syndrome
This study tests an experimental drug called zorevunersen for people with Dravet syndrome. It aims to see if the drug can reduce seizures and improve safety.
Memphis, TennesseeAges 2–17 - NCT06846606RecruitingPhase 1
Study of AUTX-703 for advanced blood cancers
This trial tests an experimental drug, AUTX-703, for people with certain blood cancers (AML or MDS) that have returned or not improved after other treatments. The goal is to see if the drug is safe and helps control the disease.
Nashville, TennesseeAges 18 years+ - NCT06850038Recruiting
Long-term study of odevixibat in Alagille syndrome
This study follows people with Alagille syndrome who are already taking or starting odevixibat (Bylvay). It looks at how well the medicine works and how safe it is over a long period of time.
Memphis, TennesseeAges Any age - NCT06747949RecruitingPhase 3
Long term extension study of dazodalibep for Sjogren's syndrome
This study gives continued access to the study drug dazodalibep for people with Sjogren's syndrome who completed a prior phase 3 study. The goal is to see how safe and effective the medication is over a longer period.
Murfreesboro, TennesseeAges 18 years+ - NCT06679855RecruitingPhase 3
Milrinone to prevent heart problems after PDA closure
This trial tests if giving milrinone before surgery to close a common heart vessel (PDA) can prevent heart issues in premature babies. It may help very premature infants who need surgery for a large PDA.
Memphis, TennesseeAges Up to 3 months - NCT06577441RecruitingPhase 2
Adding enasidenib to usual care for higher-risk MDS with IDH2 mutation
This trial tests whether adding enasidenib (a targeted pill) to the standard chemotherapy (cedazuridine-decitabine) works better than the chemotherapy alone for people with higher-risk myelodysplastic syndrome (MDS) whose cells have a specific change in the IDH2 gene.
Knoxville, TennesseeAges 18 years+ - NCT05889559Recruiting
Testing a fluid drainage method to detect leg pressure problems
This study looks at a special drainage measurement (“tissue ultrafiltration”) to better detect and treat acute compartment syndrome, a dangerous increase in pressure in the leg after major injury. It may help doctors identify who needs urgent treatment and improve outcomes after severe leg fractures or crush injuries.
Nashville, TennesseeAges 18–60 - NCT06499285RecruitingPhase 3
Study of a new drug to treat anemia in adults with low to intermediate risk MDS who need transfusions
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
Knoxville, TennesseeAges 18 years+ - NCT06501196RecruitingPhase 1
Study of BH-30236 for leukemia and high-risk MDS
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
Nashville, TennesseeAges 18 years+ - NCT06430385RecruitingPhase 1/Phase 2
Study of ION440 for MECP2 Duplication Syndrome
This trial tests an experimental medicine called ION440 for people with MECP2 Duplication Syndrome. The medicine is given as an injection into the spinal fluid, and the study aims to check its safety and how well it works.
Nashville, TennesseeAges 2–65 - NCT06247787RecruitingPhase 1
Imetelstat plus chemo for relapsed leukemia in kids
This trial tests a new drug called imetelstat combined with two chemotherapy drugs (fludarabine and cytarabine) for children and teens with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or juvenile myelomonocytic leukemia (JMML) that has come back or not responded to treatment. The goal is to find the safest dose of imetelstat and see if it helps control the cancer.
Memphis, TennesseeAges 1–18 - NCT05375968RecruitingPhase 2
Test blood-flow changes in POTS after meals
This Phase 2 study looks at how blood pools in the belly veins when you stand or eat, in people with POTS (postural tachycardia syndrome). The goal is to understand what’s driving symptoms like feeling nearly faint and whether this helps guide better care.
Nashville, TennesseeAges 18–50 - NCT05354141RecruitingPhase 3
Tested treatment with tiny lung particles for moderate to severe ARDS
This Phase 3 trial studies an “extracellular vesicle” treatment in people with moderate to severe ARDS, a serious lung breathing problem. The goal is to see whether the treatment can improve outcomes compared with standard care.
Knoxville, TennesseeAges 18–75 - NCT04851678Recruiting
Study how stress affects adults with Tourette syndrome
This study follows adults with Tourette syndrome over time to better understand how stressors affect symptoms and daily life. It may help researchers learn what factors make symptoms better or worse and improve future care.
Nashville, TennesseeAges 18 years+ - NCT04419649RecruitingPhase 2
Elritercept for anemia in lower-risk myelodysplastic syndromes
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
Memphis, TennesseeAges 18 years+ - NCT04462770RecruitingPhase 3
Clemizole trial for children and adults with Dravet syndrome
This Phase 3 study tests EPX-100 (clemizole) to help reduce seizures in people with Dravet syndrome whose seizures are not fully controlled by current anti-seizure medicines. You may consider this study if your Dravet diagnosis is confirmed and your medical situation fits the specific rules about medicines and seizure causes.
Memphis, TennesseeAges 2 years+ - NCT04278404Recruiting
Drug safety study for children already on certain medicines
This study measures how certain medicines move through the body and checks their safety in children. It may help doctors better understand dosing and side effects in kids who are already receiving these treatments, or in some kids who recently tested positive for COVID-19.
Nashville, TennesseeAges birth–20 years - NCT04165109Recruiting
Down syndrome study to test memory and thinking changes
This study enrolls adults with Down syndrome to better understand how thinking and memory develop and change over time. It may help by building a “trial-ready” group and by measuring thinking in a careful, consistent way.
Nashville, TennesseeAges 25–55 - NCT04061421RecruitingPhase 1/Phase 2
Testing new medicine combos for bone marrow disease overlap syndromes
This early-phase trial studies a new treatment plan (decitabine-related medicine with other targeted drugs, depending on the arm) for adults with MDS/MPN overlap syndromes. It aims to improve control of the disease by targeting the abnormal bone marrow cells. Because it’s Phase 1/2, the main goal is to find safe dosing and see whether it helps responses.
Nashville, TennesseeAges 18 years+
Down Syndrome trials by city in Tennessee
Where these studies are running in Tennessee
Institutions with a site for the recruiting down syndrome studies listed above.
- Vanderbilt University Medical Center · 7 studies
- Le Bonheur Children's Hospital · 4 studies
- Access Clinical Trials, Inc.
- Baptist Memorial Hospital
- Cyndya Shibao
- Direct Biologics Investigational Site
- Monroe Carell Jr. Children's Hospital at Vanderbilt
- Murfreesboro Medical Clinic Westlawn
What taking part in a down syndrome study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Down Syndrome trials in other states
Common questions
- Are there down syndrome clinical trials in Tennessee?
- Yes. We're currently tracking 93 recruiting down syndrome studies with a site in Tennessee, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a down syndrome study in Tennessee?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Tennessee to take part?
- Not necessarily. These studies have a site in Tennessee, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a down syndrome trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New down syndrome studies open in Tennessee regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.